Reference entry · GLP-1 receptor agonist (exendin-4 analog)
Exenatide
Also known as: Exendin-4 · Byetta/Bydureon (approved drug names)
- Class
- GLP-1 receptor agonist (exendin-4 analog)
- Primary targets (literature)
- GLP-1 receptor
- Regulatory context
- FDA-approved drug. RUO catalog exenatide requires batch-specific identity proof and is not trial drug product.
Overview
Exenatide is the first-in-class GLP-1 receptor agonist based on exendin-4 from Gila monster venom, with long-standing human trial literature. It anchors incretin research history before later acylated analogs like liraglutide and semaglutide.
Mechanism in research literature
GLP-1 receptor agonism with shorter native half-life than acylated successors; extended-release formulation literature adds microsphere delivery complexity.
Common research focus areas
- Foundational incretin trial and pharmacology literature
- Twice-daily vs. extended-release formulation research
- Comparator context for newer GLP-1 agonists
- Exendin-4 sequence identity for catalog material
Full literature roundup
Read the cited research summary
The first-in-class GLP-1 receptor agonist derived from exendin-4. Foundational incretin literature, mechanisms, and material-quality considerations.
Exenatide research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.